Previous 10 | Next 10 |
home / stock / ibrx / ibrx articles
U.S. stocks traded higher, with the Nasdaq Composite gaining more than 100 points on Monday. Here are some big stocks recording gains in today&rsqu...
Gainers Apollomics, Inc. (NASDAQ: APLM) shares surged 88.4% to $1.07 stoma multiforme with PTPRZ-MET fusion. BIO-key International, Inc. (NASDAQ...
U.S. stocks traded mixed, with the Nasdaq Composite gaining more than 100 points on Friday. Here are some big stocks recording gains in today&rsquo...
Gainers ABVC BioPharma, Inc. (NASDAQ: ABVC) shares jumped 231.6% to $2.8190 after the company announced it entered into a term sheet to license t...
U.S. stocks traded lower, with the Nasdaq Composite falling more than 90 points on Thursday. Here are some big stocks bucking the trend and recordi...
U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session. ...
Gainers InMed Pharmaceuticals Inc. (NASDAQ: INM) shares climbed 169% to $1.56 after the company announced it selected a lead Alzheimer's ...
U.S. stocks traded higher Tuesday, with the Nasdaq Composite gaining over 100 points. Here are some big stocks recording gains in the trading sessi...
SAN DIEGO, Oct. 09, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shar...
News, Short Squeeze, Breakout and More Instantly...
2024-07-09 10:10:00 ET July 9, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Tech, Biotech, Cleantech and Mining Sectors. The newest tech company is involved in AI and Blo...
2024-07-07 01:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Multiple patients treated across the U.S. with ANKTIVA less than eight weeks after FDA approval of first-in-class cytokine immunotherapy for BCG unresponsive non-muscle invasive bladder cancer ANKTIVA launch initiates the next era of immunotherapy beyond checkpoint inhibitors that is based on...